ID

17911

Description

A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00083473

Link

https://clinicaltrials.gov/show/NCT00083473

Keywords

Versions (1)
  1. 10/7/16 10/7/16 -
Uploaded on

October 7, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Leukemia, Lymphocytic, Chronic NCT00083473

English

Eligibility Leukemia, Lymphocytic, Chronic NCT00083473

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients must have a confirmed diagnosis of cll or small lymphocytic lymphoma (sll) based upon the revised nci-sponsored working group guidelines for cll;
Description

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Data type

boolean

Alias
UMLS CUI [1]
C0023434
UMLS CUI [2]
C0855095
relapsed or refractory disease after previous chemotherapy treatment;
Description

Recurrent disease Post Prior Chemotherapy | Refractory Disease Post Prior Chemotherapy

Data type

boolean

Alias
UMLS CUI [1,1]
C0277556
UMLS CUI [1,2]
C0687676
UMLS CUI [1,3]
C1514457
UMLS CUI [2,1]
C1514815
UMLS CUI [2,2]
C0687676
UMLS CUI [2,3]
C1514457
age > 18 years;
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
adequate renal function with creatinine <= 1.5 mg/dl;
Description

Renal function | Creatinine measurement, serum

Data type

boolean

Alias
UMLS CUI [1]
C0232804
UMLS CUI [2]
C0201976
adequate liver function with alkaline phosphatase <= 2.5 x upper limit of normal, serum glutamic oxaloacetic transaminase (sgot), and serum glutamic pyruvic transaminase (sgpt) <= 2.5 x upper limit of normal; and total bilirubin <= 2.0 x upper limit of normal;
Description

Liver function | Alkaline phosphatase measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Serum total bilirubin measurement

Data type

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C0201850
UMLS CUI [3]
C0201899
UMLS CUI [4]
C0201836
UMLS CUI [5]
C1278039
adequate bone marrow function as determined by having platelets > 50,000/mm3 without transfusion in the preceding 2 weeks and an absolute neutrophil count (anc) => 1,500 cells/mm3 without growth factor support; unless cytopenias due to marrow infiltration;
Description

Bone Marrow Function | Platelet Count measurement | Blood Transfusion | Absolute neutrophil count | Growth Factor Supportive care | Cytopenia Due to Bone marrow infiltration

Data type

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [2]
C0032181
UMLS CUI [3]
C0005841
UMLS CUI [4]
C0948762
UMLS CUI [5,1]
C0018284
UMLS CUI [5,2]
C0344211
UMLS CUI [6,1]
C0010828
UMLS CUI [6,2]
C0678226
UMLS CUI [6,3]
C3854434
able to give informed consent;
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
a minimum of 4 weeks must have elapsed from the completion of any previous treatment regimen, including radiation and biologic therapies (6 weeks if a prior nitrosourea or mitomycin c, 12 weeks if radioimmunotherapy) to treatment on day 1 cycle 1. patients must have recovery from treatment-associated toxicity(ies);
Description

Prior Therapy Complete | Therapeutic radiology procedure | Biological treatment | Nitrosourea | Mitomycin | Radioimmunotherapy | Toxic effect Associated with Therapeutic procedure | Patients Recovered

Data type

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0205197
UMLS CUI [2]
C1522449
UMLS CUI [3]
C1531518
UMLS CUI [4]
C0028210
UMLS CUI [5]
C0002475
UMLS CUI [6]
C0085101
UMLS CUI [7,1]
C0600688
UMLS CUI [7,2]
C0332281
UMLS CUI [7,3]
C0087111
UMLS CUI [8,1]
C0030705
UMLS CUI [8,2]
C0521108
a predicted life expectancy of at least 6 months; and
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
eastern cooperative oncology group (ecog) performance status of 0, 1, or 2.
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
more than three systemic treatment regimens for cll/sll (excluding immunotherapies and biologic therapies);
Description

systemic therapy Quantity Chronic Lymphocytic Leukemia | systemic therapy Quantity Small Lymphocytic Lymphoma | Immunotherapy | Biological treatment

Data type

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0023434
UMLS CUI [2,1]
C1515119
UMLS CUI [2,2]
C1265611
UMLS CUI [2,3]
C0855095
UMLS CUI [3]
C0021083
UMLS CUI [4]
C1531518
concurrent malignancy that the patient has not been free of for at least 5 years, excluding curatively treated carcinoma-in-situ or non-melanoma skin cancer;
Description

Malignant Neoplasms | Carcinoma in Situ curative treatment | Skin carcinoma curative treatment

Data type

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C0007099
UMLS CUI [2,2]
C1273390
UMLS CUI [3,1]
C0699893
UMLS CUI [3,2]
C1273390
any pregnant or lactating females. females of childbearing potential must have a negative pregnancy test and all male and female patients of reproductive potential must agree to use adequate birth control;
Description

Pregnancy | Breast Feeding | Childbearing Potential Pregnancy test negative | Fertility Contraceptive methods

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C0427780
UMLS CUI [4,1]
C0015895
UMLS CUI [4,2]
C0700589
known hiv-positive patients;
Description

HIV Seropositivity

Data type

boolean

Alias
UMLS CUI [1]
C0019699
any underlying medical conditions or circumstances that would contraindicate therapy with study treatment, affect compliance or impair evaluation of study endpoints;
Description

medical condition Contraindication Therapies, Investigational | medical condition Compliance behavior Limited | medical condition Interferes with research results | Condition Contraindication Therapies, Investigational | Condition Compliance behavior Limited | Condition Interferes with research results

Data type

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0522473
UMLS CUI [1,3]
C0949266
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C1321605
UMLS CUI [2,3]
C0439801
UMLS CUI [3,1]
C3843040
UMLS CUI [3,2]
C0521102
UMLS CUI [3,3]
C0683954
UMLS CUI [4,1]
C0348080
UMLS CUI [4,2]
C0522473
UMLS CUI [4,3]
C0949266
UMLS CUI [5,1]
C0348080
UMLS CUI [5,2]
C1321605
UMLS CUI [5,3]
C0439801
UMLS CUI [6,1]
C0348080
UMLS CUI [6,2]
C0521102
UMLS CUI [6,3]
C0683954
receiving investigational agents within 4 weeks of the study treatment; and
Description

Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0013230
known allergy to reagents in the study.
Description

Hypersensitivity Reagents Investigational

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0034760
UMLS CUI [1,3]
C1517586
Back to the top of the page

Similar models

Eligibility Leukemia, Lymphocytic, Chronic NCT00083473

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma
Item
patients must have a confirmed diagnosis of cll or small lymphocytic lymphoma (sll) based upon the revised nci-sponsored working group guidelines for cll;
boolean
C0023434 (UMLS CUI [1])
C0855095 (UMLS CUI [2])
Recurrent disease Post Prior Chemotherapy | Refractory Disease Post Prior Chemotherapy
Item
relapsed or refractory disease after previous chemotherapy treatment;
boolean
C0277556 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C1514457 (UMLS CUI [1,3])
C1514815 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C1514457 (UMLS CUI [2,3])
Age
Item
age > 18 years;
boolean
C0001779 (UMLS CUI [1])
Renal function | Creatinine measurement, serum
Item
adequate renal function with creatinine <= 1.5 mg/dl;
boolean
C0232804 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
Liver function | Alkaline phosphatase measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Serum total bilirubin measurement
Item
adequate liver function with alkaline phosphatase <= 2.5 x upper limit of normal, serum glutamic oxaloacetic transaminase (sgot), and serum glutamic pyruvic transaminase (sgpt) <= 2.5 x upper limit of normal; and total bilirubin <= 2.0 x upper limit of normal;
boolean
C0232741 (UMLS CUI [1])
C0201850 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
C1278039 (UMLS CUI [5])
Bone Marrow Function | Platelet Count measurement | Blood Transfusion | Absolute neutrophil count | Growth Factor Supportive care | Cytopenia Due to Bone marrow infiltration
Item
adequate bone marrow function as determined by having platelets > 50,000/mm3 without transfusion in the preceding 2 weeks and an absolute neutrophil count (anc) => 1,500 cells/mm3 without growth factor support; unless cytopenias due to marrow infiltration;
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0032181 (UMLS CUI [2])
C0005841 (UMLS CUI [3])
C0948762 (UMLS CUI [4])
C0018284 (UMLS CUI [5,1])
C0344211 (UMLS CUI [5,2])
C0010828 (UMLS CUI [6,1])
C0678226 (UMLS CUI [6,2])
C3854434 (UMLS CUI [6,3])
Informed Consent
Item
able to give informed consent;
boolean
C0021430 (UMLS CUI [1])
Prior Therapy Complete | Therapeutic radiology procedure | Biological treatment | Nitrosourea | Mitomycin | Radioimmunotherapy | Toxic effect Associated with Therapeutic procedure | Patients Recovered
Item
a minimum of 4 weeks must have elapsed from the completion of any previous treatment regimen, including radiation and biologic therapies (6 weeks if a prior nitrosourea or mitomycin c, 12 weeks if radioimmunotherapy) to treatment on day 1 cycle 1. patients must have recovery from treatment-associated toxicity(ies);
boolean
C1514463 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2])
C1531518 (UMLS CUI [3])
C0028210 (UMLS CUI [4])
C0002475 (UMLS CUI [5])
C0085101 (UMLS CUI [6])
C0600688 (UMLS CUI [7,1])
C0332281 (UMLS CUI [7,2])
C0087111 (UMLS CUI [7,3])
C0030705 (UMLS CUI [8,1])
C0521108 (UMLS CUI [8,2])
Life Expectancy
Item
a predicted life expectancy of at least 6 months; and
boolean
C0023671 (UMLS CUI [1])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0, 1, or 2.
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
systemic therapy Quantity Chronic Lymphocytic Leukemia | systemic therapy Quantity Small Lymphocytic Lymphoma | Immunotherapy | Biological treatment
Item
more than three systemic treatment regimens for cll/sll (excluding immunotherapies and biologic therapies);
boolean
C1515119 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0023434 (UMLS CUI [1,3])
C1515119 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0855095 (UMLS CUI [2,3])
C0021083 (UMLS CUI [3])
C1531518 (UMLS CUI [4])
Malignant Neoplasms | Carcinoma in Situ curative treatment | Skin carcinoma curative treatment
Item
concurrent malignancy that the patient has not been free of for at least 5 years, excluding curatively treated carcinoma-in-situ or non-melanoma skin cancer;
boolean
C0006826 (UMLS CUI [1])
C0007099 (UMLS CUI [2,1])
C1273390 (UMLS CUI [2,2])
C0699893 (UMLS CUI [3,1])
C1273390 (UMLS CUI [3,2])
Pregnancy | Breast Feeding | Childbearing Potential Pregnancy test negative | Fertility Contraceptive methods
Item
any pregnant or lactating females. females of childbearing potential must have a negative pregnancy test and all male and female patients of reproductive potential must agree to use adequate birth control;
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C3831118 (UMLS CUI [3,1])
C0427780 (UMLS CUI [3,2])
C0015895 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
HIV Seropositivity
Item
known hiv-positive patients;
boolean
C0019699 (UMLS CUI [1])
medical condition Contraindication Therapies, Investigational | medical condition Compliance behavior Limited | medical condition Interferes with research results | Condition Contraindication Therapies, Investigational | Condition Compliance behavior Limited | Condition Interferes with research results
Item
any underlying medical conditions or circumstances that would contraindicate therapy with study treatment, affect compliance or impair evaluation of study endpoints;
boolean
C3843040 (UMLS CUI [1,1])
C0522473 (UMLS CUI [1,2])
C0949266 (UMLS CUI [1,3])
C3843040 (UMLS CUI [2,1])
C1321605 (UMLS CUI [2,2])
C0439801 (UMLS CUI [2,3])
C3843040 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C0683954 (UMLS CUI [3,3])
C0348080 (UMLS CUI [4,1])
C0522473 (UMLS CUI [4,2])
C0949266 (UMLS CUI [4,3])
C0348080 (UMLS CUI [5,1])
C1321605 (UMLS CUI [5,2])
C0439801 (UMLS CUI [5,3])
C0348080 (UMLS CUI [6,1])
C0521102 (UMLS CUI [6,2])
C0683954 (UMLS CUI [6,3])
Investigational New Drugs
Item
receiving investigational agents within 4 weeks of the study treatment; and
boolean
C0013230 (UMLS CUI [1])
Hypersensitivity Reagents Investigational
Item
known allergy to reagents in the study.
boolean
C0020517 (UMLS CUI [1,1])
C0034760 (UMLS CUI [1,2])
C1517586 (UMLS CUI [1,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial